Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Employment agrmnt
OptimizeRx Corp (OPRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "OptimizeRx Reports Second Quarter 2023 Financial Results"
06/09/2023 SC 13G First Light Asset Management, LLC reports a 10.3% stake in OptimizeRx Corporation
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "OptimizeRx Reports First Quarter 2023 Financial Results - Total revenue of $13.0 million - GAAP net loss per share of $ - Non-GAAP net loss per share of $ ROCHESTER, Mich. – May 10, 2023 – OptimizeRx Corp. , a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended March 31, 2023. Quarterly comparisons are to the same year-ago period."
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/06/2023 SC 13G/A BlackRock Inc. reports a 6.1% stake in OPTIMIZERX CORP
03/14/2023 8-K Other Events  Interactive Data
03/10/2023 10-K Annual Report for the period ended December 31, 2022
03/10/2023 10-Q/A Quarterly Report for the period ended September 30, 2022 [amend]
03/10/2023 10-Q/A Quarterly Report for the period ended June 30, 2022 [amend]
03/10/2023 10-Q/A Quarterly Report for the period ended March 31, 2022 [amend]
03/10/2023 10-K/A Annual Report for the period ended December 31, 2021 [amend]
03/08/2023 8-K Quarterly results
Docs: "OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results - Q4 revenue of $19.7 million, down 3% year-over-year and up 30% quarter-over-quarter - Q4 gross profit increased 1% year-over-year to $12.5 million as gross margins increased from 61% to 63% - Generated $10.7 million in cash flow from operations in 2022 - Repurchased 1.2 million shares during 2022 at an average price of $16.49 per share - Exited 2022 with six Real-World Data Artificial Intelligence deals ROCHESTER, Mich. – March 8, 2023 – OptimizeRx Corp. , a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2022. Twelve Months Ended December 31, Key Performance Indicators * 2022 2021 Average revenu..."
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
08/10/2022 8-K/A Quarterly results
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
Docs: "OPTIMIZERx CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2022 December 31, 2021 ASSETS Current Assets Cash and cash equivalents $ 87,392,970 $ 84,681,770 Accounts receivable, net 18,732,849 24,800,585 Prepaid expenses and other 4,280,843 5,630,655 Total Current Assets 110,406,662 115,113,010 Property and equipment, net 143,337 143,818 Other Assets Goodwill 22,673,820 14,740,031 Intangible assets, net 13,933,072 10,646,654 Security deposits and other assets 12,860 12,859 Total Other Assets 36,898,265 25,728,364 TOTAL ASSETS $ 147,448,264 $ 140,985,192 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Accounts payable – trade $ 1,296,041 $ 606,808 Accrued expenses 1,638,791 2,902,836 Revenue share payable 2,376,836 4,378,216 Current portion of lease obligations 87,673 90,..."
06/13/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/09/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/04/2022 8-K Quarterly results
04/25/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/17/2022 8-K Unregistered Sales of Equity Securities  Interactive Data
03/04/2022 8-K Quarterly results
02/28/2022 10-K Annual Report for the period ended December 31, 2021
02/24/2022 8-K Quarterly results
02/15/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "OptimizeRx Announces Preliminary Fourth Quarter 2021 Financial Results, Introduces New Key Performance Indicators and Provides Initial 2022 Guidance"
02/11/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2022 SC 13G VANGUARD GROUP INC reports a 6.1% stake in OptimizeRx Corp.
01/27/2022 SC 13G/A BlackRock Inc. reports a 15% stake in OPTIMIZERX CORP
01/26/2022 SC 13G/A BlackRock Inc. reports a 15% stake in OPTIMIZERX CORP
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy